Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
Research Characteristics: Triple-action peptide analogue targeting GLP-1, GIP, and glucagon receptor pathways Studied for effects on receptor binding, signaling, and endocrine regulation Examined in laboratory research for its role in energy balance and multi-pathway modulation THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
What the dose-response data shows, how it differs from titration, and the cost and safety risks.
December 15, 2025: MDL Created for Ozempic Vision Loss Lawsuits In a significant move, the Judicial Panel on Multidistrict Litigation has approved the creation of a new MDL for Ozempic vision loss lawsuits
Shima Hadidchi, MD , provides attentive care and education for patients beginning their Semaglutide (GLP-1) treatment
European Union considerations EU member states apply their own interpretations of the Medicinal Products Directive to peptide imports
.png)
